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Potentially of Value in the Diagnostic Evaluation of
Suspected Heart Failure With Preserved Ejection Fraction
Thomas Weber, MD,*† Siegfried Wassertheurer, DI,‡§ Michael F. O’Rourke, MD,
Anton Haiden, MD,* Robert Zweiker, MD,¶ Martin Rammer, MD,* Bernhard Hametner, DI,‡
Bernd Eber, MD*
Wels, Salzburg, Vienna, and Graz, Austria; and Sydney, Australia
Objectives This study sought to test whether measures of pulsatile arterial function are useful for diagnosing heart failure
with preserved ejection fraction (HFPEF), in comparison with and in addition to tissue Doppler echocardiography
(TDE).
Background Increased arterial stiffness and wave reflections are present in most patients with HFPEF.
Methods Patients with dyspnea as a major symptom were categorized as having HFPEF or no HFPEF, based on invasively
derived filling pressures and natriuretic peptide levels. Pulse wave velocity (PWV) was measured invasively (aor-
tic PWV). Aortic pulse pressure (aoPP) and its components (incident pressure wave height, forward wave ampli-
tude; augmented pressure; backward wave amplitude [Pb]) were quantified noninvasively.
Results Seventy-one patients were classified as HFPEF and 65 as no HFPEF (223 patients had intermediate results). Pa-
tients with HFPEF were older, more often had hypertension and diabetes, and had larger left atria and higher left
ventricular mass. Brachial pulse pressure (bPP), aoPP, and all measures of arterial stiffness and wave reflec-
tions were higher in HFPEF patients. Receiver-operating curve analysis–derived area under the curve (AUC) val-
ues for separating HFPEF from no HFPEF were 0.823 for E/E= at the medial annulus, the best TDE parameter;
0.816 for bPP; and 0.867, 0.851, and 0.825 for aortic PWV, aoPP, and Pb, respectively. Adding measures of
pulsatile function to TDE resulted in an increase in AUC to 0.875 (bPP; p  0.03) and 0.901 (aoPP; p  0.005).
In comparison with a TDE-based algorithm, net reclassification improvement was 32.9% (p  0.0001).
Conclusions Measures of pulsatile arterial hemodynamics may complement TDE for the diagnosis of HFPEF. (Pulsatile and
Steady State Hemodynamics in Diastolic Heart Failure; NCT00720525) (J Am Coll Cardiol 2013;61:1874–83)
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.013An increase in the pulsatile components of blood pressure
(systolic blood pressure [SBP], pulse pressure [PP]) is a
major risk factor for developing heart failure in general (1)
and heart failure with preserved ejection fraction (HFPEF)
in particular (2). An impairment of arterial pulsatile func-
tion in HFPEF patients has been described repeatedly
(3–5). Mechanistic studies have identified a relationship
between diastolic dysfunction and increased arterial stiffen-
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echocardiogram on the basis of impaired left ventricular
filling and increased filling pressures (9,10). However,
measurement of blood pressure or arterial properties is not
recommended in recent guidelines of major cardiovascular
societies on the evaluation of diastolic dysfunction and on
the diagnosis of HFPEF (9,10).
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May 7, 2013:1874–83 Pulsatile Hemodynamics and HFPEFIn this trial, we evaluated whether simple (brachial pulse
pressure [bPP]) or more precise measures of pulsatile
arterial function can be used for diagnosis of HFPEF in
patients with dyspnea on exertion and preserved systolic
function. All patients underwent invasive cardiac examina-
tion, giving us the opportunity to base our diagnosis upon
invasively determined left ventricular end-diastolic pressures
(LVEDPs), supported by plasma levels of N-terminal pro–
B-type natriuretic peptides (NT-proBNP) (10). Therefore,
we were able to test the diagnostic properties of markers of
pulsatile arterial function against and in combination with
commonly used, recommended echocardiographic parame-
ters (9,10).
Methods
Patients. We prospectively included patients undergoing car-
diac catheterization for suspected coronary artery disease
(CAD) at our institutions, presenting with a major symptom of
dyspnea on exertion, if left ventricular ejection fraction was
normal (50%) (10). Exclusion criteria were unstable clinical
conditions, rhythm other than stable sinus rhythm or stable
paced rhythm, more than mild valvular disease, pericardial
constriction, and primary pulmonary hypertension. The study
was conducted according to the Declaration of Helsinki,
approved by our regional ethics committees, and all patients
gave written informed consent. The trial was registered at
ClinicalTrials.gov (NCT00720525).
Hypertension was present with repeated measurements
140 mm Hg SBP and/or 90 mm Hg diastolic blood
ressure or permanent antihypertensive drug treatment.
iabetes mellitus was defined as a fasting blood glucose
oncentration 7 mmol/l or antihyperglycemic drug treat-
ent. Creatinine clearance was estimated using the
ockcroft-Gault formula. For this study, we defined signif-
cant CAD as at least 1 diameter stenosis 50% or greater in
t least 1 coronary vessel, or prior coronary revascularization.
he extent of CAD was defined using a modified scoring
ystem (“angioscore”) (11). Pulmonary functional testing
as a regular part of the diagnostic workup of our patients,
s well as chest x-ray.
iagnosis of HFPEF. On the basis of LVEDP and
lasma levels of NT-proBNP, with cutoff levels according
o recently published recommendations (10) and cardiology
extbooks (12), we categorized patients as having HFPEF
ith LVEDP 16 mm Hg, and NT-proBNP levels 220
pg/ml, the HFPEF group. We excluded the condition with
LVEDP12 mm Hg and NT-proBNP levels120 pg/ml,
the no HFPEF group. All other patients fell into the
intermediate category, which we labeled possible HFPEF.
LVEDP was measured automatically using the built-in
software of our coronary angiography systems (Siemens Artis
Zee with AXIOM Sensis hemodynamic recording system,
Siemens Healthcare, Erlangen, Germany, in Wels, Austria,
and Philips Allura Xper FD 10/10, Philips, Eindhoven, the
Netherlands, in Graz, Austria) during cardiac catheterizationbefore contrast cineangiography,
using 6-F fluid-filled pigtail
catheters. All pressure tracings
were visually inspected for com-
pliance with the standard defini-
tion of LVEDP, i.e., the pressure
after the “A” wave at the onset of
left ventricular isovolumetric
contraction, coincident with the
electrocardiogram’s R-wave (13).
We carefully performed flushing
and zeroing, and tried to avoid
artifacts. In 21 patients, we com-
pared LVEDPs simultaneously
measured with our fluid-filled
system and with high-fidelity
sensor-tip pressure catheters
(5-F Millar SPC-454D, Millar
Instruments, Houston, Texas),
which were adjusted to baseline
electronically, calibrated under
saline, connected to a Millar
PCU-2000 unit. Values were in
excellent agreement, with a mean
difference of 0.5  3.2 mm Hg
(Online Fig. 1). In addition, re-
producibility of LVEDP was
good. In 20 patients, mean dif-
ference between repeated mea-
surements was 0.5 2.1 mm Hg
(Online Fig. 2).
Plasma levels of NT-proBNP
were measured, using the commer-
cially available electrochemilumi-
nescence immunoassay “ECLIA”
on the Elecsys 1020 analyzer
(Roche Diagnostics, Mannheim,
Germany).
Arterial pulsatile function. Bra-
chial blood pressure was mea-
sured with a validated (14), au-
tomated, oscillometric, sphygmomanometer (Omron M5-I,
Omron Healthcare, Kyoto, Japan). Estimation of central
(aortic) blood pressures and arterial wave reflections was
performed noninvasively with the SphygmoCor system
Version 9 (AtCor Medical, Sydney, Australia), using the
technique of pulse waveform analysis (11) by nurses not
involved in other aspects of the study. In addition, the
absolute heights of the forward and the backward pressure
waves were quantified, using wave separation analysis with
the recently developed and validated ARCSolver method
(15). Arterial stiffness was assessed invasively (aortic pulse
wave velocity [aoPWV]), and noninvasively (carotid–
femoral pulse wave velocity). A detailed description of our
methods to assess pulsatile arterial function is available in
Abbreviations
and Acronyms
aoPP  aortic pulse
pressure
aoPWV  aortic pulse
wave velocity
AP  augmented pressure
AUC  area under the
curve
bPP  brachial pulse
pressure
CAD  coronary artery
disease
E/E=med  E/E= at the
medial annulus
HFPEF  heart failure with
preserved ejection fraction
LVEDP  left ventricular
end-diastolic pressure
NRI  Net reclassification
improvement
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
P1  incident pressure
wave height
Pb  amplitude of the
backward wave
Pf  amplitude of the
forward wave
PP  pulse pressure
PWV  pulse wave velocity
ROC  receiver-operating
characteristic
SBP  systolic blood
pressure
TDE  tissue Doppler
echocardiographythe Online Appendix.
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Pulsatile Hemodynamics and HFPEF May 7, 2013:1874–83Echocardiography. A detailed 2-dimensional and Doppler
echocardiogram according to the recommendations of the
American Society of Echocardiography (16) was obtained in
all patients immediately before or after measurement of
arterial stiffness/wave reflections, using a Philips iE33
(Philips) or a Vivid 7 (GE Healthcare, Waukesha, Wiscon-
Selected Baseline CharacteristicsTable 1 Selected Baseline Characteristics
HFPEF
(n  71)
LVEDP, mm Hg 20 [22–25]
NT-proBNP, pg/ml 412 [290–696]
Men 47 (66.2)
Age, yrs 67.7 8.6
NYHA functional class II/III 63 (88.7)/8 (11.3)
Pulmonary congestion 8 (11.3)
Prior decompensation 3 (4.2)
Body height, cm 168.8 9.3
Body weight, kg 83.8 17.9
Hypertension treated/untreated/no 66/4/1 (93/5.6/1.4)
Diabetes 21 (29.6)
HbA1c 5.9 [5.5–6.5]
Creatinine clearance, ml/min 68 [56–83]
Hb, g/dl 13.8 [12.9–14.6]
Anemia (Hb 12.5 g/dl women, 13 g/dl men) 15 (21.1)
Coronary artery disease 41 (57.7)
AngioScore 2.0 [0.0–7.8]
Pulmonary function testing: any obstruction 20 (28.2)
Pulmonary function testing: mild/moderate/
severe obstruction
6/10/4 (8.5/14.1/5.6)
ACE-I or ARB 50 (70.4)
Beta-blockers 51 (71.8)
Calcium channel blockers 27 (38.0)
Diuretic agents 24 (33.8)
Centrally acting antihypertensive agents 7 (9.9)
Spironolactone 2 (2.8)
NO donators 15 (21.1)
Number antihypertensive agents 2.5 1.4
Invasive measurements
EF angio, % 71 [63–80]
LV syst, mm Hg 171 [153–185]
Aortic (invasive) SBP, mm Hg 167 24
Aortic (invasive) DBP, mm Hg 74 13
Aortic (invasive) MBP, mm Hg 111 16
Aortic (invasive) PP, mm Hg 91 21
Aortic PWV, m/s 10.8 [8.9–12.6]
Heart rate, beats/min 68 [63–76]
Right atrial, mean, mm Hg* 4 [2–6]
Right ventricular SBP, mm Hg* 37 [30–42]
Right ventricular DBP, mm Hg* 3 4
Pulmonary arterial SBP, mm Hg* 32 [29–41]
Pulmonary arterial DBP, mm Hg* 14 [10–17]
PCW, mean, mm Hg* 12 5
CO, l/min* 4.7 [4.0–6.0]
PVR, dyne s/cm5* 184 117
TPR, dyne s/cm5* 340 [300–406]
SVR, dyne s/cm5* 1,789 [1,588–1,988]sin) machine in Wels and Graz, respectively. For pulsedwave tissue Doppler imaging, the sample volume was
located at the medial and at the lateral border of the mitral
annulus in the apical 4-chamber view, where we obtained
early diastolic mitral annulus velocity (E=), late diastolic
velocity (A=), and peak systolic velocity (S=).
Statistics. Data are presented as mean  SD if normally
Possible HFPEF
(n  223)
No HFPEF
(n  65) p Value
16 [14–19] 9 [7–12] 0.0001
120 [60–192] 52 [35–77] 0.0001
158 (70.9) 49 (75.4) 0.499
64.0 9.3 56.7 8.6 0.0001
213 (95.5)/10 (4.5) 61 (93.8)/4 (6.2) 0.12
1 (0.1) 0 (0) 0.0001
2 (0.3) 0 (0) 0.065
170.9 9.3 171.3 9.0 0.25
84.4 16.0 84.4 17.2 0.98
171/17/35 (76.7/7.6/15.7) 34/7/24 (52.3/10.8/36.9) 0.0001
55 (24.7) 9 (13.8) 0.084
5.7 [5.5–6.2] 5.7 [5.5–6.2] 0.055
73 [61–83] 78 [68–88] 0.003
14.3 [13.4–15.0] 14.9 [13.9–15.3] 0.0007
25 (11.2) 5 (7.7) 0.04
110 (49.3) 26 (40.0) 0.12
0.0 [0.0–3.0] 0.0 [0.0–2.0] 0.0008
56 (25.1) 23 (35.4) 0.17
25/25/6 (11.2/11.2/2.7) 11/10/2 (16.9/15.4/3.1) 0.29
126 (56.5) 20 (30.8) 0.0001
112 (50.2) 20 (30.8) 0.0001
39 (17.5) 7 (10.8) 0.0001
67 (30.0) 12 (18.5) 0.11
4 (1.8) 0 (0) 0.0008
2 (0.9) 0 (0) 0.26
30 (13.5) 9 (13.8) 0.28
1.7 1.3 1.1 1.1 0.0001
74 [67–80] 74 [68–81] 0.23
145 [134–184] 124 [111–136] 0.0001
146 21 125 19 0.0001
70 10 68 10 0.0044
100 13 91 12 0.0001
76 17 57 15 0.0001
8.8 [7.4–10.2] 7.4 [6.4–8.7] 0.0001
67 [60–74] 69 [63–78] 0.39
3 [1–5] 2 [1–3] 0.04
29 [24–34] 24 [21–28] 0.0001
2 4 1 3 0.36
27 [23–31] 21 [18–25] 0.0001
10 [8–13] 8 [6–11] 0.0018
8 4 6 3 0.0001
5.3 [4.3–6.0] 5.3 [4.6–5.7] 0.55
148 77 134 76 0.18
258 [207–325] 222 [140–255] 0.0001
1,473 [1,235–1,721] 1,415 [1,240–1,606] 0.0003
Continued on the next pagedistributed, median (lower and upper quartile) if non-
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May 7, 2013:1874–83 Pulsatile Hemodynamics and HFPEFnormally distributed, and as numbers (percentages) if cate-
gorical. Continuous and categorical data were compared
across all 3 diagnostic groups, using Kruskal-Wallis analysis
of variance and the chi-square test, respectively. In order to
perform the comparison between pulsatile hemodynamics
and echocardiography in clear-cut diagnostic groups, the
main analysis was carried out in patients with established
diagnosis (HFPEF) and established exclusion (no HFPEF)
of HFPEF: we constructed receiver-operating characteristic
(ROC) curves to illustrate the diagnostic performance of
measures of pulsatile arterial function and of echocardio-
ContinuedTable 1 Continued
HFPEF
(n  71)
Noninvasive measurements of blood pressures
and arterial function
Brachial SBP, mm Hg 147 [130–163]
Brachial DBP, mm Hg 83 [74–89]
Brachial PP, mm Hg 64 [55–77]
MBP, mm Hg 105 [93–115]
Aortic SBP, mm Hg 137 [121–152]
Aortic DBP, mm Hg 84 [74–90]
Aortic PP, mm Hg 54 16
AIx 31 9
AP, mm Hg 17 9
P1, mm Hg 37 9
Heart rate, beats/min 63 12
LVETI, ms 359 24
WSA Pf, mm Hg 34 10
WSA Pb, mm Hg 22 7
cfPWV, m/s 9.8 2.4
Echocardiographic parameters
End-diastolic volume, ml 122 38
End-systolic volume, ml 45 24
Stroke volume, ml 77 26
LV mass, g/m2 134 38
EF, % 68 11
LA diameter, cm/m2 2.1 0.3
LA volume, ml/m2 22.7 7.3
CO, l/min 4.5 1.6
E, cm/s 71.7 24.7
A, cm/s 75.6 20.7
E/A 1.04 0.62
S=med, cm/s 6.3 1.2
E=med, cm/s 5.3 1.6
E/E=med 14.4 5.9
S=lat, cm/s 7.7 2.2
E=lat, cm/s 7.3 2.5
E/E=lat 10.6 4.3
E/E=comb 12.6 4.8
Values are median [interquartile range], n (%), or mean  SD. The p values are from analysis of v
ndicates statistical significance. *Measured in 129 patients (21, 77, and 31 HFPEF, possible HFP
ACE-I angiotensin-converting enzyme inhibitor; AIx augmentation index; AP augmented p
utput; E=comb  (E/E=med  E/E=lat)/2; E=lat  E= at the lateral annulus; E=med  E= at the
ngiography; HbA1c  glycosylated hemoglobin; HFPEF  heart failure with preserved ejection fra
ventricular ejection time index; LV syst left ventricular systolic; MBPmean blood pressure; NO
P1  incident pressure wave height; Pb  amplitude of the backward wave; PCW  pulmonary
vascular resistance; PWV  pulse wave velocity; S=lat  S= at the lateral annulus; S=med  S= a
pulmonary resistance; WSA  wave separation analysis.graphic parameters and to compare both methods, using thearea under the curve (AUC) and z-statistic. Because this
approach may not represent clinical routine ideally (where
we have to deal with intermediate cases as well), we
performed additional analyses, testing the combination of
no HFPEF and possible HFPEF groups against HFPEF
patients (for diagnosis of HFPEF) and the combination
of HFPEF and possible HFPEF groups against no HFPEF
patients (for exclusion of HFPEF). Because possible
HFPEF patients actually may represent suffering from a
milder course (or an earlier stage) of HFPEF, we also
performed multiple linear regression analysis, coding no
Possible HFPEF
(n  223)
No HFPEF
(n  65) p Value
136 [125–149] 127 [120–128] 0.0001
80 [73–89] 81 [77–85] 0.46
57 [48–65] 45 [40–55] 0.0001
99 [91–109] 97 [92–103] 0.0095
124 [113–138] 117 [110–126] 0.0001
81 [75–90] 82 [78–87] 0.57
45 13 36 10 0.0001
27 11 23 12 0.0006
13 7 9 5 0.0001
32 8 27 7 0.0001
66 12 68 13 0.057
352 21 343 20 0.0007
29 8 24 6 0.0001
18 6 14 4 0.0001
9.0 2.1 7.9 1.8 0.0001
120 40 117 29 0.82
43 25 40 19 0.57
78 24 77 19 0.89
121 37 108 32 0.0003
68 9 67 8 0.49
1.96 0.33 1.9 0.3 0.0001
18.5 7.1 16.1 5.5 0.0001
4.8 1.5 4.7 1.2 0.21
60.1 17.8 61.8 13.1 0.0032
78.3 17.4 72.9 17.9 0.066
0.80 0.33 0.89 0.27 0.0009
7.0 1.3 7.7 1.4 0.0001
5.8 1.6 6.9 1.8 0.0001
10.8 3.4 9.4 2.4 0.0001
8.4 2.0 9.1 2.4 0.0003
7.9 2.4 9.1 2.5 0.0002
8.1 2.9 7.2 2.1 0.0001
9.4 2.9 8.3 2.0 0.0001
and the chi-square test, as appropriate. Based on Bonferroni’s correction, a p value of 0.0003
no HFPEF patients, respectively).
; ARB angiotensin receptor blocker; cfPWV carotid–femoral pulse wave velocity; CO cardiac
annulus; Hb  hemoglobin; DBP  diastolic blood pressure; EF angio  ejection fraction by
LA  left atrial; LV  left ventricular; LVEDP  left ventricular end-diastolic pressure; LVETI  left
xide; NT-proBNPN-terminal pro–B-type natriuretic peptide; NYHANew York Heart Association;
y wedge pressure; Pf  amplitude of the forward wave; PP  pulse pressure; PVR  pulmonary
edial annulus; SBP  systolic blood pressure; SVR  systemic vascular resistance; TPR  totalariance
EF, and
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medial
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Pulsatile Hemodynamics and HFPEF May 7, 2013:1874–83To determine the most effective combination of diagnos-
tic tests to predict the presence or absence of HFPEF, we
applied multiple stepwise logistic regression with the use of
a p value of 0.1 or less for entry into the model and a p value
of 0.2 or higher for removal from the model. The predicted
and the actually observed values for the presence/absence of
HFPEF were cross-classified, and the percentage of cases
correctly classified was obtained. The AUC’s for uni-, bi-,
and multivariable models to predict HFPEF were com-
pared, using the z-statistic.
Net reclassification improvement (NRI), as compared
with echocardiography, as recommended by recent guide-
lines (10), was calculated according to the method of
Pencina et al. (17). In addition, to provide a potentially
usable classification, we applied a stepwise approach to
determine cutoff values leading to 95% sensitivity and
specificity for each parameter and parameter set, respec-
tively. Starting (according to the guidelines) with E/E= at
the medial annulus (E/E=med) as the initial marker, we
modified the upper and lower limits incrementally, followed
by a recount, until we achieved the supposed sensitivity and
specificity. Subjects remaining between the upper and lower
limits had then been reclassified using various pulsatile
measures, following the same procedure. This was done for
any parameter combination as well as any parameter order,
because a modified order leads to different cutoffs. The huge
number of calculations and comparisons was performed by
customized software. Statistical analysis was performed
using MedCalc software version 11.6.0 (MedCalc Comp,
Mariakerke, Belgium), and Matlab 7.8.0 (MathWorks,
Natick, Massachusetts).
Results
Baseline characteristics. Mean patient age was 63.4 years,
70.7% were men, and 83.5% patients had hypertension,
23.7% diabetes, and 49.4% CAD. Pulmonary comorbidities
were present in 32.1%; 93.8% of our patients were prospec-
tively categorized as New York Heart Association (NYHA)
functional class II, and 6.2% as NYHA functional class III,
with no significant differences among our diagnostic groups
(Table 1, Online Table 1).
Applying our diagnostic criteria, 71 patients were diag-
nosed with HFPEF, in 65 patients we excluded the condi-
tion, and 223 patients fell into the intermediate category
(possible HFPEF).
We observed a graded increase of age, presence of
hypertension, number of antihypertensive drugs used, and
extent of CAD across our diagnostic groups, with the
highest values observed in the HFPEF group.
Hemodynamic measures. We found a statistically highly
significant, graded increase of brachial SBP, mean blood
pressure, and PP across diagnostic groups, with the highest
values observed in the HFPEF group, which was even more
pronounced when blood pressures were measured invasively
during cardiac catheterization. In the subgroup of patients dundergoing right heart catheterization (n  129), we found
the same differences for right-sided pressures and total
pulmonary resistance. Heart rates as well as cardiac output
did not differ across groups.
All parameters of pulsatile arterial function showed the
same statistically highly significant increase across diagnos-
tic groups. In addition, the duration of ejection was pro-
longed in HFPEF.
Echocardiographic parameters. Again, we observed a sta-
tistically highly significant distribution of measurements:
patients with HFPEF had higher values for wall thickness,
left ventricular mass, left atrial dimensions, and estimated
filling pressures (E/E=) and lower values for tissue Doppler
echocardiography (TDE) measurements, as compared with
patients in the no HFPEF group. Patients with possible
HFPEF fell into the intermediate category.
Diagnostic performance—ROC analysis. The AUCs in
ROC analysis, when measures of arterial function and
echocardiographic parameters were used to differentiate
HFPEF from no HFPEF, are shown in Table 2 and Online
able 2. The best diagnostic performance of an echocardio-
raphic parameter was observed for E/E=med with an AUC
f 0.823. The AUC for bPP, which is readily available even
n primary care, was 0.816 (p  0.88 for comparison with
/E=med). Measures of central arterial function, including
he antegrade pressure wave (incident pressure wave height
P1], amplitude of the forward wave [Pf]), the reflected
ressure wave (augmented pressure [AP], amplitude of the
ackward wave [Pb]), their combination (aortic PP), and
ortic stiffness (aoPWV), had diagnostic capacities in the
ame range (Fig. 1). The highest AUC was found for
oPWV (0.867); the highest AUC of a noninvasive mea-
urement was found for aoPP (0.851). According to the
-statistic, the AUCs for the arterial parameters were not
tatistically significantly different from E/E=med, with p
alues 0.20 for all, respectively.
When we investigated clinically relevant subgroups, we
bserved a similar diagnostic performance of E/E= and the
rterial parameters in men and women, patients with and
ithout CAD, and patients up to and above 62 years of age
Table 2, Online Table 2). When we excluded patients from
he analysis in whom coronary revascularization was per-
ormed (leaving 56 patients in the HFPEF and 56 patients
n the no HFPEF-group), the diagnostic performance of
easures of pulsatile function and of echocardiographic
arameters was even better, but still comparable (AUCs for
oPP and E/E=med were 0.863 and 0.867, respectively)
Online Table 3).
In exploratory analysis, when HFPEF was diagnosed or
xcluded only on the basis of LVEDP, AUCs were some-
hat lower in general, but measures of pulsatile arterial
unction remained as good as or even better (aoPP) than
chocardiographic parameters for the differentiation be-
ween HFPEF and no HFPEF (Online Tables 4 and 5).
When we included the possible HFPEF group and tested the
iagnostic value of the various measures to diagnose HFPEF
or diffe
Table 1
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and no HFPEF groups), AUCs were lower for all parameters, but
measures of pulsatile arterial function and echocardiographic
parameters again did not differ significantly (Online Table 6). The
same was true when we included the possible HFPEF group and
tested the diagnostic value of the various measures to exclude
HFPEF (no HFPEF group versus the combination of the
possible HFPEF and HFPEF groups) (Online Table 7).
Multivariable models. Applying multivariable logistic re-
gression analysis with HFPEF or no HFPEF as outcome
variable, E/E=med correctly classified 77% of patients. In
comparison, bPP correctly classified 75.7% of patients.
Values for central arterial parameters were in the same range
(Fig. 2, Table 3). Adding 1 parameter of arterial function to
the model with E/E=med improved model fit, up to 86.5%
of patients could be correctly identified, and AUCs were
significantly higher (Figs. 1 and 2, Online Table 8). bPP in
addition to E/E=med significantly increased the AUC (p 
0.03), but was inferior to the combination of E/E=med and
aoPP (p  0.009 for comparison). In the final models,
including clinical parameters, medications, echocardio-
graphic measures, and 1 parameter of pulsatile function, up
to 90.1% of patients could be correctly classified. Selecting
aoPP or Pb as parameters of pulsatile function led to the
Diagnostic Performance of Key Indexes of Steady and Pulsatile ArtTable 2 Diagnostic Performance of Key Indexes of Steady and
All Patients
(N  136)
CAD
(n  67)
No CAD
(n  69)
Brachial PP 0.816 (0.741–0.878) 0.783 (0.666–0.875) 0.834 (0.725–0.913) 0
p  0.0001 p  0.0001 p  0.0001
Aortic PP 0.851 (0.780–0.906) 0.817 (0.704–0.901) 0.878 (0.777–0.944) 0
p  0.0001 p  0.0001 p  0.0001
AP 0.804 (0.727–0.867) 0.774 (0.656–0.868) 0.825 (0.714–0.906) 0
p  0.0001 p  0.0001 p  0.0001
P1 0.812 (0.736–0.874) 0.790 (0.673–0.880) 0.818 (0.707–0.901) 0
p  0.0001 p  0.0001 p  0.0001
Pf 0.813 (0.738–0.875) 0.782 (0.665–0.874) 0.839 (0.731–0.917) 0
p  0.0001 p  0.0001 p  0.0001
Pb 0.825 (0.751–0.885) 0.800 (0.685–0.888) 0.838 (0.729–0.915) 0
p  0.0001 p  0.0001 p  0.0001
cfPWV 0.744 (0.661–0.816) 0.770 (0.649–0.865) 0.789 (0.672–0.879) 0
p  0.0001 p  0.0001 p  0.0001
aoPWV 0.867 (0.798–0.919) 0.874 (0.771–0.943) 0.850 (0.743–0.924) 0
p  0.0001 p  0.0001 p  0.0001
E/A 0.514 (0.426–0.601) 0.597 (0.470–0.715) 0.575 (0.448–0.695) 0
p  0.514 p  0.165 p  0.334
LV mass 0.718 (0.627–0.798) 0.678 (0.537–0–799) 0.728 (0.599–0.834) 0
p  0.0001 p  0.021 p  0.0004
LA volume 0.762 (0.679–0.833) 0.769 (0.648–0.865) 0.764 (0.639–0.863) 0
p  0.0001 p  0.0001 p  0.0001
E/E=med 0.823 (0.748–0.883) 0.773 (0.654–0.866) 0.846 (0.738–0.922) 0
p  0.0001 p  0.0001 p  0.0001
E/E=comb 0.801 (0.723–0.865) 0.756 (0.636–0.853) 0.820 (0.708–0.902) 0
p  0.0001 p  0.0001 p  0.0001
Values are areas under the curve (95% confidence intervals) in receiver-operating curve analysis f
aoPWV  aortic pulse wave velocity; CAD  coronary artery disease; other abbreviations as inhighest AUCs (Fig. 2, Table 4, Online Table 9).In multiple linear regression models including possible
HFPEF patients (with intermediate coding, see the previ-
ous text), pulsatile hemodynamics significantly predicted the
degree of HFPEF (Online Table 10).
Incremental diagnostic value—NRI. When we used all
echocardiographic parameters with cutoff values as sug-
gested in recent guidelines (10) in the subset of 58 HFPEF
patients and 57 no HFPEF patients in whom complete
datasets including left ventricular mass and left atrial vol-
umes were available, 42 patients were classified correctly, 13
incorrectly, and 60 patients remained unclassified. The
combination with 1 measure of pulsatile arterial function led
to a highly significant NRI of up to 32.9 % for noninvasive
parameters (aoPP) (Table 5).
Using only E/E=med as a first step to diagnose or exclude
HFNEF, as suggested in recently published guidelines (10),
and the combination with 2 parameters of pulsatile arterial
function led to similar results and highly significant NRIs
(Online Tables 11 to 13, Online Fig. 3).
Discussion
In this study, we observed in a cohort of middle-age and
elderly patients presenting as clinically stable, without overt
Function and of Echocardiographic Measurementstile Arterial Function and of Echocardiographic Measurements
Men
 96)
Women
(n  40)
Age <62 yrs
(n  70)
Age >62 yrs
(n  66)
0.739–0.899) 0.814 (0.659–0.919) 0.748 (0.606–0.889) 0.802 (0.672–0.933)
0.0001 p  0.0001 p  0.0006 p  0.0001
0.753–0.908) 0.867 (0.722–0.954) 0.799 (0.682–0.916) 0.806 (0.679–0.932)
0.0001 p  0.0001 p  0.0001 p  0.0001
0.704–0.882) 0.810 (0.670–0.950) 0.789 (0.670–0.909) 0.723 (0.581–0.864)
0.0001 p  0.0001 p  0.0001 p  0.002
0.741–0.908) 0.828 (0.678–0.978) 0.749 (0.609–0.888) 0.800 (0.675–0.925)
0.0001 p  0.0001 p  0.0005 p  0.0001
0.727–0.899) 0.828 (0.682–0.974) 0.752 (0.608–0.896) 0.793 (0.665–0.920)
0.0001 p  0.0001 p  0.0005 p  0.0001
0.726–0.896) 0.833 (0.698–0.969) 0.784 (0.665–0.904) 0.749 (0.608–0.890)
0.0001 p  0.0001 p  0.0005 p  0.0001
0.674–0.864) 0.690 (0.515–0.864) 0.737 (0.608–0.865) 0.595 (0.419–0.771)
0.0001 p  0.033 p  0.0003 p  0.289
0.820–0.947) 0.845 (0.712–0.978) 0.784 (0.652–0.917) 0.817 (0.684–0.951)
0.0001 p  0.0001 p  0.0001 p  0.0001
0.377–0.617) 0.560 (0.377–0.743) 0.560 (0.437–0.679) 0.621 (0.491–0.740)
 0.962 p  0.521 p  0.467 p  0.094
0.636–0.850) 0.736 (0.561–0.911) 0.795 (0.670–0.889) 0.676 (0.538–0.795)
0.0001 p  0.008 p  0.0001 p  0.071
0.672–0.869) 0.752 (0.583–0.920) 0.813 (0.696–0.899) 0.626 (0.494–0.746)
0.0001 p  0.003 p  0.0001 p  0.138
0.730–0.902) 0.852 (0.723–0.980) 0.844 (0.738–0.920) 0.766 (0.645–0.862)
0.0001 p  0.0001 p  0.0001 p  0.0001
0.698–0.885) 0.828 (0.696–0.960) 0.825 (0.715–0.905) 0.710 (0.584–0.816)
0.0001 p  0.0001 p  0.0001 p  0.002
rentiating patients with and without HFPEF.
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Pulsatile Hemodynamics and HFPEF May 7, 2013:1874–83that pulsatile arterial hemodynamics are abnormal in those
with HFPEF. The principle findings were: 1) that nonin-
vasively measured indexes of arterial function may provide a
clue for the diagnosis of HFPEF with equal precision to
echocardiography and TDE; and 2) when performed in
combination with echocardiography and TDE, indexes may
improve accuracy of diagnosis.
We based our diagnosis on invasively derived left ven-
tricular filling pressures with cutoff values according to
generally accepted guidelines (10) and major textbooks (12),
in combination with plasma levels of natriuretic peptides
(10). This approach allowed us to investigate the diagnostic
performance of pulsatile hemodynamics independently of
echocardiographic measures and to compare pulsatile he-
modynamics and echocardiography against each other and
in combination. Of note, although echocardiography was
not part of the diagnostic algorithm, we observed typical
structural (left atrial enlargement, left ventricular hypertro-
phy) and functional (mitral inflow, TDE patterns, right-
sided pressures) abnormalities in our HFPEF patients,
strongly supporting the internal validity of our data and the
assumption that the patients’ symptoms were due to heart
failure. In the absence of overt congestion, otherwise well-
validated epidemiological criteria for diagnosing heart fail-
Figure 1
Diagnostic Performance of Pulsatile Hemodynamics
and Echocardiography in Differentiating Between
HFPEF and No HFPEF—ROC Analysis
Receiver-operating characteristic (ROC) curve comparison of pulsatile hemody-
namics versus echocardiography versus their combination for differentiating
HFPEF from no HFPEF patients. Areas under the curve were 0.823, 0.816,
0.851, 0.875, and 0.901 for E/E=med, bPP, aoPP, E/E=med  bPP, and
E/E=med  aoPP, respectively. The areas under the curve from pulsatile hemo-
dynamics plus echocardiography were superior to echocardiography alone
(p  0.03 with bPP, p  0.005 with aoPP). aoPP  aortic pulse pressure;
bPP  brachial pulse pressure; E/E=med  E/E= at the medial annulus;
HFPEF  heart failure with preserved ejection fraction.ure were less useful in our population with early/less severeheart failure, as these criteria mainly depend on clinical signs
of volume overload.
We did not exclude patients with pulmonary disease,
because this can be an important comorbidity in heart
failure patients (18), a fact that is indeed confirmed by our
data. We also did not exclude patients with CAD from our
analysis, because HFPEF and CAD frequently coexist (19).
he diagnostic value of pulsatile hemodynamics in our study
as not substantially different in patients with and without
AD, and the extent of CAD (angioscore) did not reach
tatistical significance in the multivariable models to predict
FPEF. In addition, 16.2% of our patients (statistically not
ifferent among our diagnostic groups) underwent coronary
evascularization as a consequence of diagnostic testing and
ymptoms (dyspnea was taken as angina-equivalent, or
ypical angina was present in addition to dyspnea). When
e excluded these patients from the analysis, the diagnostic
erformance of measures of pulsatile function was even
mproved, corroborating our main findings, but also sug-
esting that treatable causes of exertional dyspnea (in this
ase: myocardial ischemia) should be excluded before label-
ng patients as primarily HFPEF.
Pathophysiological mechanisms underlying our findings
re known, at least to some extent: diastolic function is
nversely related to arterial stiffness (PWV) and wave
eflection (AIx) (6,7). Against this background, various
roups have reported increased arterial stiffness (8,20,21),
ecreased aortic distensibility (4), and increased wave reflec-
ions (5,6) in HFPEF patients. Recently, increased wave
eflections were strong, independent predictors of new-
nset heart failure in a large, population-based study (22).
his may be related to unfavorable myocardial–arterial
Figure 2
Diagnostic Performance of Pulsatile Hemodynamics
and Echocardiography in Differentiating Between
HFPEF and No HFPEF—Logistic Regression
Diagnostic performance of selected echocardiographic measurements and of
key measures of pulsatile arterial function to differentiate between HFPEF and
no HFPEF patients, expressed as a percentage of patients correctly identified
in uni- and multivariable logistic regression models. aoPWV  aortic pulse
wave velocity; AP  augmented pressure; LA  left atrial; LV  left ventricular;
P1  incident pressure wave height; Pb  amplitude of the backward wave;
Pf  amplitude of the forward wave; other abbreviations as in Figure 1.
Tables
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(23). Conversely, the exact cause of the key symptoms of
stable, compensated HFPEF— exertional dyspnea and
fatigue—is an area of active research: Prior studies (3,24)
suggest that increased arterial stiffness is a contributor.
However, the mechanisms are likely complex and multifac-
torial, perhaps also including impaired chronotropic reserve
and vasodilation (25), and even factors beyond the heart
(reduced arterial–venous oxygen content difference) may
play a role (26).
In our study, HFPEF patients were older than the no
HFPEF patients, and increased arterial stiffness (and pulse
pressures [PPs]) are a hallmark of arterial aging. The
diagnostic performance of pulsatile hemodynamics, how-
ever, was not different between younger and older patients,
and—in the multivariable models—independent of age.
Still, before incorporating these measures into formal diag-
nostic algorithms, it needs to be established that arterial
stiffness/wave reflections are elevated in HFPEF patients as
compared with age- and blood pressure–matched asymp-
tomatic controls. This has been shown up to now only for
age-matched controls in 2 previous series (21,24).
If these results are confirmed in subsequent studies with
more typical HFPEF patients and closely age- and sex-
matched controls, then how might they be applied in
clinical routine? aoPWV is an invasive measurement, but
the finding that models including aoPWV yielded the best
Univariable Logistic Regression Models Differentiating Between HFTable 3 Univariable Logistic Regression Models Differentiating
OR (95 % CI) p Value
E/E=med 1.536 (1.312–1.799) 0.0001
LA volume, per ml 1.176 (1.097–1.260) 0.0001
LV mass, per g 1.022 (1.009–1.035) 0.0006
P1, per mm Hg 1.170 (1.106–1.237) 0.0001
Pf, per mm Hg 1.197 (1.118–1.281) 0.0001
AP, per mm Hg 1.215 (1.128–1.310) 0.0001
Pb, per mm Hg 1.274 (1.167–1.391) 0.0001
Aortic PP, per mm Hg 1.133 (1.083–1.185) 0.0001
Brachial PP, per mm Hg 1.097 (1.061–1.134) 0.0001
Aortic PWV, per m/s 2.197 (1.678–2.877) 0.0001
cfPWV, per m/s 1.574 (1.280–1.937) 0.0001
LVETI, per ms 1.031 (1.014–1.048) 0.0003
AUC  area under the curve; CI  confidence interval; OR  odds ratio; other abbreviations as in
Multivariable Logistic Regression Model Differentiating Between HTable 4 Multivariable Logistic Regression Model Differentiating
OR (95 % CI) p Value
P
E/E=med 1.204 (0.978–1.484) 0.081
Aortic PP, per mm Hg 1.094 (1.029–1.164) 0.004
Age, per yr 1.135 (1.053–1.224) 0.001
ACE-I or ARB, yes  1 7.772 (1.053–1.224) 0.004
Beta-blocker, yes  1 9.211 (2.000–42.408) 0.004
NO donator, yes  1 0.209 (0.033–1.315) 0.095S=, LA volume, LV mass, sex, diabetes, AngioScore, mean blood pressure, heart rate, calcium channel bl
Abbreviations as in Tables 1 and 3.diagnostic accuracy is of interest as a proof of concept.
Conversely, bPP, a crude estimate of pulsatile load, is
readily available in primary care and might be useful as a
first-line test in symptomatic patients. In addition, in
combination with echocardiography, bPP improves diag-
nostic accuracy. Among the more precise measures of
pulsatile hemodynamics, aoPP seems to be most useful in
the diagnostic process. Its superiority over bPP probably
reflects the fact that aortic pressures are directly “seen” by
the heart and are different from brachial pressures due to the
phenomenon of PP amplification, which in turn depends on
the stiffness of the aorta and the large arteries, and on wave
reflections. Indeed, measures of wave reflections (Pb, AP)
approximate the diagnostic value of aoPP, either alone or in
combination with TDE, and can be combined with aoPP
for further refinement of the diagnostic algorithm. Recently,
methods for noninvasive measurement of central blood
pressures, using regular oscillometric sphygmomanometers
(27), have been developed and validated, which may en-
hance the availability of measures of pulsatile arterial func-
tion. Of note, effective arterial elastance, which has been
used to describe arterial properties (7), was less useful to
discriminate our diagnostic groups. This is in line with
previous reports (28) and may be due to the fact that this
measure is not a pure measure of pulsatile hemodynamics,
but lumps together pulsatile and steady components of the
arterial load (29).
and No HFPEF Patientseen HFPEF and No HFPEF Patients
Percent Correctly Classified AUC 95% CI AUC
77.04% 0.823 0.748–0.883
70.08% 0.762 0.679–0.833
63.48% 0.718 0.627–0.798
75.74% 0.812 0.736–0.874
73.53% 0.813 0.738–0.875
69.85% 0.804 0.727–0.867
73.55% 0.825 0.751–0.885
77.21% 0.851 0.780–0.906
75.74% 0.816 0.741–0.878
75.74% 0.867 0.798–0.919
68.18% 0.744 0.661–0.816
63.25% 0.683 0.598–0.760
1 and 2.
and No HFPEF Patientsween HFPEF and No HFPEF Patients
Correctly
sified AUC (95% CI)
Improvement Above E/E=med
p Value
.09% 0.952 (0.894–0.983) 0.0002PEFBetwFPEFBet
ercent
Clas
90ocker, and LVETI did not enter the model.
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Pulsatile Hemodynamics and HFPEF May 7, 2013:1874–83Our study focuses on the role of impaired pulsatile
hemodynamics as markers of long-standing/uncontrolled
hypertension in the diagnosis of HFPEF. With respect to
the treatment of HFPEF, some aspects may be of interest:
in trials with uncontrolled hypertension and high PPs (in
the range of our HFPEF group), the reduction in blood
pressure was related to the improvement of diastolic func-
tion (30), whereas in patients with controlled blood pressure
and relatively low PPs (in the range of our intermediate
group) (31), treatment with antihypertensive drugs (induc-
ing only a minor decrease of PP of 1.7 mm Hg) showed no
benefit on clinical outcomes.
Study limitations. Some limitations need to be considered:
rst, we excluded patients with atrial fibrillation due to the
nability to perform stable hemodynamic measurements.
econd, although NT-proBNP levels were used for HFPEF
ase definition in the present study, we recognize there is
ignificant controversy in this regard, and that NT-proBNP
evels can be relatively low in HPFEF patients who are
linically noncongested and have nondilated left ventricles
32). Third, we did not perform exercise testing. This
hould have given additional information (33), not limited
o, but particularly regarding the relatively large group with
ossible HFPEF. In these patients (euvolemic, preserved
F, and unexplained exertional dyspnea), marked increases
n LVEDP, PCW, and systolic PA pressures during exer-
ise can establish the diagnosis of HFPEF (32). With
espect to pulsatile hemodynamics, a major increase in
roximal afterload and arterial stiffening with moderate
xercise has been found in HFPEF patients (34), and
changes in estimated filling pressures have been related to
changes in wave reflection during a submaximal exercise test
in HFPEF patients (35). More work is needed to address
which of the measures of pulsatile function (and their
changes during exercise) are related to the fundamental
factors that comprise exercise function (peak oxygen uptake,
Combined Approach to Diagnose or Exclude HFPTable 5 Combined Approach to Diagnose or
Brachial PP, mm Hg
Ao PP, mm Hg
Ao PWV, m/s
cfPWV, m/s
Classified Not Classified Co
ECHO 55 60
ECHO  brachial PP 73 42
ECHO  ao PP 80 35
ECHO  ao PWV 91 24
ECHO  cfPWV 73 42
Values are n or %. The combined approach to diagnose or exclude HF
mass index, left atrial volume index) with cutoff values recommended i
of heart failure with normal left ventricular ejection fraction (10), and 1
optimized for a low rate of incorrectly classified patients. Classificat
improvement (NRI) was as compared with classification based on ECH
ao  aortic; other abbreviations as in Table 1.cardiac output, arteriovenous oxygen difference). Due to thereferral to cardiac catheterization, we included more men
than women into the study, leading to a relatively high
proportion of men with HFPEF. The diagnostic value of
pulsatile hemodynamics was independent from sex, how-
ever. Still, our findings should be replicated in other
populations, particularly in typical HFPEF populations
(elderly, predominantly female) with appropriate age- and
sex-matched controls and in clinically diagnosed HFPEF
patients. In the present study, we focused on stable patients
without overt signs of congestion, where the diagnosis was
less obvious and had to be based on invasive and laboratory
measures. This may possibly explain the high rate of
patients in the intermediate diagnostic group in our study,
although the presence of a gradual onset of HFPEF rather
than a simple presence or absence could be another expla-
nation. Finally, extreme group analysis (considering only
HFPEF and no HFPEF patients) allows for comparison
between clearly established diagnostic groups, but likely
overestimates the diagnostic utility estimates (AUCs, NRIs)
for clinical routine use.
Conclusions
We have found that measures of pulsatile arterial function,
notably bPP and aoPP and measures of wave reflection, may
complement TDE in patients with unexplained exertional
dyspnea in stable, nondecompensated patients.
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APPENDIX
For supplementary figures and tables and an expanded Methods section,
please see the online version of this paper.
